Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PTEN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PTEN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTEN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTEN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PTEN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTEN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTEN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTEN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTEN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:1903362 | Colorectum | AD | regulation of cellular protein catabolic process | 109/3918 | 255/18723 | 2.14e-15 | 6.08e-13 | 109 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
GO:1903050 | Colorectum | AD | regulation of proteolysis involved in cellular protein catabolic process | 92/3918 | 221/18723 | 2.04e-12 | 3.19e-10 | 92 |
GO:0045732 | Colorectum | AD | positive regulation of protein catabolic process | 92/3918 | 231/18723 | 3.85e-11 | 4.47e-09 | 92 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:0045862 | Colorectum | AD | positive regulation of proteolysis | 129/3918 | 372/18723 | 4.04e-10 | 3.46e-08 | 129 |
GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
GO:2000058 | Colorectum | AD | regulation of ubiquitin-dependent protein catabolic process | 68/3918 | 164/18723 | 1.82e-09 | 1.31e-07 | 68 |
GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:2001233 | Colorectum | AD | regulation of apoptotic signaling pathway | 119/3918 | 356/18723 | 2.14e-08 | 1.21e-06 | 119 |
GO:0050821 | Colorectum | AD | protein stabilization | 73/3918 | 191/18723 | 3.02e-08 | 1.64e-06 | 73 |
GO:1903364 | Colorectum | AD | positive regulation of cellular protein catabolic process | 62/3918 | 155/18723 | 4.66e-08 | 2.51e-06 | 62 |
GO:0010810 | Colorectum | AD | regulation of cell-substrate adhesion | 81/3918 | 221/18723 | 4.80e-08 | 2.55e-06 | 81 |
GO:1903320 | Colorectum | AD | regulation of protein modification by small protein conjugation or removal | 86/3918 | 242/18723 | 9.43e-08 | 4.65e-06 | 86 |
GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
GO:0150115 | Colorectum | AD | cell-substrate junction organization | 44/3918 | 101/18723 | 2.38e-07 | 9.81e-06 | 44 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516662 | Oral cavity | NEOLP | Human T-cell leukemia virus 1 infection | 50/1112 | 222/8465 | 6.91e-05 | 5.23e-04 | 3.29e-04 | 50 |
hsa0522261 | Oral cavity | NEOLP | Small cell lung cancer | 24/1112 | 92/8465 | 6.04e-04 | 3.31e-03 | 2.08e-03 | 24 |
hsa0414061 | Oral cavity | NEOLP | Autophagy - animal | 32/1112 | 141/8465 | 1.17e-03 | 5.56e-03 | 3.49e-03 | 32 |
hsa0152142 | Oral cavity | NEOLP | EGFR tyrosine kinase inhibitor resistance | 20/1112 | 79/8465 | 2.47e-03 | 1.03e-02 | 6.49e-03 | 20 |
hsa0521441 | Oral cavity | NEOLP | Glioma | 18/1112 | 75/8465 | 7.23e-03 | 2.61e-02 | 1.64e-02 | 18 |
hsa052354 | Oral cavity | NEOLP | PD-L1 expression and PD-1 checkpoint pathway in cancer | 20/1112 | 89/8465 | 1.03e-02 | 3.47e-02 | 2.18e-02 | 20 |
hsa0406841 | Oral cavity | NEOLP | FoxO signaling pathway | 27/1112 | 131/8465 | 1.07e-02 | 3.54e-02 | 2.22e-02 | 27 |
hsa0451053 | Oral cavity | NEOLP | Focal adhesion | 71/1112 | 203/8465 | 7.25e-16 | 7.68e-14 | 4.83e-14 | 71 |
hsa0516571 | Oral cavity | NEOLP | Human papillomavirus infection | 90/1112 | 331/8465 | 2.75e-12 | 1.75e-10 | 1.10e-10 | 90 |
hsa0520873 | Oral cavity | NEOLP | Chemical carcinogenesis - reactive oxygen species | 68/1112 | 223/8465 | 5.39e-12 | 2.86e-10 | 1.80e-10 | 68 |
hsa0541572 | Oral cavity | NEOLP | Diabetic cardiomyopathy | 62/1112 | 203/8465 | 4.45e-11 | 1.57e-09 | 9.89e-10 | 62 |
hsa0415151 | Oral cavity | NEOLP | PI3K-Akt signaling pathway | 79/1112 | 354/8465 | 8.42e-07 | 9.92e-06 | 6.24e-06 | 79 |
hsa0421871 | Oral cavity | NEOLP | Cellular senescence | 43/1112 | 156/8465 | 1.05e-06 | 1.19e-05 | 7.49e-06 | 43 |
hsa0407171 | Oral cavity | NEOLP | Sphingolipid signaling pathway | 36/1112 | 121/8465 | 1.11e-06 | 1.21e-05 | 7.64e-06 | 36 |
hsa0521552 | Oral cavity | NEOLP | Prostate cancer | 28/1112 | 97/8465 | 3.15e-05 | 2.57e-04 | 1.62e-04 | 28 |
hsa0516672 | Oral cavity | NEOLP | Human T-cell leukemia virus 1 infection | 50/1112 | 222/8465 | 6.91e-05 | 5.23e-04 | 3.29e-04 | 50 |
hsa0522271 | Oral cavity | NEOLP | Small cell lung cancer | 24/1112 | 92/8465 | 6.04e-04 | 3.31e-03 | 2.08e-03 | 24 |
hsa0414071 | Oral cavity | NEOLP | Autophagy - animal | 32/1112 | 141/8465 | 1.17e-03 | 5.56e-03 | 3.49e-03 | 32 |
hsa0152152 | Oral cavity | NEOLP | EGFR tyrosine kinase inhibitor resistance | 20/1112 | 79/8465 | 2.47e-03 | 1.03e-02 | 6.49e-03 | 20 |
hsa0521451 | Oral cavity | NEOLP | Glioma | 18/1112 | 75/8465 | 7.23e-03 | 2.61e-02 | 1.64e-02 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.404T>A | p.Ile135Lys | p.I135K | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389G>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | | c.593N>A | p.Met198Lys | p.M198K | P60484 | protein_coding | deleterious(0) | benign(0.285) | TCGA-AC-A2FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PTEN | SNV | Missense_Mutation | | c.384N>C | p.Lys128Asn | p.K128N | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.28N>C | p.Ser10Arg | p.S10R | P60484 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | rs786201995 | c.70G>A | p.Asp24Asn | p.D24N | P60484 | protein_coding | deleterious(0) | benign(0.012) | TCGA-AR-A1AM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PTEN | SNV | Missense_Mutation | | c.367C>G | p.His123Asp | p.H123D | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTEN | SNV | Missense_Mutation | | c.370N>A | p.Cys124Ser | p.C124S | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PI3KBETA INHIBITOR AZD8186 | | 25544636 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | TEMSIROLIMUS | TEMSIROLIMUS | 11504908,23674493 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Temsirolimus | TEMSIROLIMUS | 27016228 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PF-04691502 | PF-04691502 | 21750219 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PANITUMUMAB | PANITUMUMAB | 19223544 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Oxaliplatin | OXALIPLATIN | 24100628 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | DETD-35 | | 27048951 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | cisplatin | CISPLATIN | |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Copanlisib | COPANLISIB | 27672108 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Fulvestrant | FULVESTRANT | 26733612 |